Frost & Sullivan Accolade for Ferring Pharmaceuticals

LONDON - The 2008 Frost & Sullivan European Human Growth Hormone Competitive
Strategy Leadership Award is presented to Ferring Pharmaceuticals. The award
is in recognition of Ferring’s initiatives in providing no-needle injection
for human growth hormone (hGH). The company offers ZOMAJET 2 VISION and
ZOMAJET VISION X, innovative no-needle delivery systems for its human growth
hormone, ZOMACTON.

(Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

These novel, no-needle delivery systems are poised to help Ferring to not
only sustain its market share in the European growth hormones market, but
also to expand its presence in the hGH market worldwide.

“Drug delivery systems provide strategic differentiation to successfully
increase sales for companies established in the hGH market,” notes Frost &
Sullivan Research Analyst Prabakar Sampath. “Through its innovation in
no-needle devices, and clinical evidence showing the high level of childrens’
preference for no-needle hGH administration, Ferring has shown leadership in
meeting the needs of the paediatric population in this therapy area.”

The majority of end users of hGH are children under the age of fifteen.
Patient compliance is an issue for treatment with drugs that have to be
administered on a daily basis. Frost & Sullivan’s end user analysis suggests
that over 30 per cent of children using traditional methods of injection are
likely to stop using hGH due to the inconvenience caused. This poor
compliance is attributed to ‘needle-phobia’ and pain caused while
administering injections.

A strategic partnership with Antares has enabled Ferring to provide
pioneering, no-needle delivery devices for ZOMACTON. Ferring launched the
ZOMAJET 2 VISION in Europe in 2002. It was one of the early providers of
no-needle systems for hGH, making it an ideal choice for drug administration
among the paediatric population.

Ferring is strongly committed to increasing physician awareness. For over
two decades, it has been sponsoring training programmes hosted by the
European Society for Paediatric Endocrinology (ESPE). These programmes are
aimed at promoting physician awareness of new trends and treatments in the
endocrinology domain.

“The company also encourages discussions and interactions between older
and younger paediatric endocrinologists,” states Sampath. “The sizeable
educational grant provided by Ferring for such training programmes reflects
its commitment to ensuring quality medical education for young
endocrinologists.”

The Frost & Sullivan Award for Competitive Strategy Leadership is
presented to the company whose competitive strategy has yielded significant
gains in market share during the research period. Often, the recognised
company has taken advantage of recent market changes that facilitate the
introduction of never-before seen methods of capturing and solidifying market
presence. Alternatively, the Award recipient may have executed an innovative
strategy within the existing competitive landscape, empowering the company to
overtake the competition. In either case, the company captures the attention
of the competition, which quickly adjusts in order to protect its own market
position. Frost & Sullivan analysts expect such innovations to produce
lasting, precedent-setting trends in the industry.

Frost & Sullivan Best Practices Awards recognise companies in a variety
of regional and global markets for demonstrating outstanding achievement and
superior performance in areas such as leadership, technological innovation,
customer service, and strategic product development. Industry analysts
compare market participants and measure performance through in-depth
interviews, analysis, and extensive secondary research in order to identify
best practices in the industry.

About Ferring Pharmaceuticals

Headquartered in Switzerland, Ferring Pharmaceuticals is a
research-driven, specialty biopharmaceutical group active in global markets.
The company identifies, develops and markets innovative products in the areas
of endocrinology, gastroenterology, urology, infertility and obstetrics.

Ferring has its own operating subsidiaries in 45 countries and markets
its products in more than 70 countries. To learn more about Ferring or our
products please visit www.ferring.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best in class positions in growth, innovation
and leadership. The company’s Growth Partnership Service provides the CEO and
the CEO’s Growth Team with disciplined research and best practice models to
drive the generation, evaluation and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from 31 offices on six continents. To join our Growth Partnership,
please visit www.frost.com.

Contact:
Ciara Jamie Connolly, Senior Events & Promotions Executive EMEA,
Best Practices, Frost & Sullivan, ciara.connolly@frost.com,
P: +44-(0)-207-915-7868, F: +44-(0)-207-730-3343, www.frost.com

Source: Frost & Sullivan

Ciara Jamie Connolly, Senior Events & Promotions Executive EMEA, Best Practices, Frost & Sullivan, +44-(0)-207-915-7868, fax, +44-(0)-207-730-3343, ciara.connolly at frost.com ; Photo: https://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO